Evaluation of periostin in case of bronchoostructive diseases


DOI: https://dx.doi.org/10.18565/therapy.2021.8.22-29

Baranov D.Z., Trofimov V.I., Lapin S.V., Mazing A.V., Kholopova I.V., Kuznetsova D.A., Moshnikova A.N., Blinova T.V.

Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
Abstract. Currently, an active search for minimally invasive laboratory markers available for use in routine clinical practice, which have high sensitivity and specificity and are of diagnostic value in bronchoobstructive diseases is carrying out.
The aim of the research is to study periostin as an allergic inflammation marker and indicator of the severity of obstructive disorders and their reversibility in patients with bronchial asthma, chronic obstructive pulmonary disease (COPD) and their combination (ACO, from English «asthma–COPD overlap»).
Material and methods. The study involved 87 patients who underwent periostin determination by EIA methodic, spirometry, including a bronchodilator test. Statistical processing was carried out by nonparametric methods due to the absence of normal distribution of periostin.
Results. The level of periostin in patients with bronchial asthma was higher than in COPD and ACO patients. Among patients with asthma, its higher values were fixed in case of allergic and mixed variant comparatively with the infectious-dependent one. Patients with bronchial asthma and COPD with a burdened allergic anamnesis had an increased periostin comparatively to similar patients without sensitization. Periostin was higher in patients with bronchial asthma exacerbation than in patients in remission. A positive correlation was demonstrated between periostin and an increase in FEV1 after bronchodilator test, and a negative correlation – with Gensler index before the test.
Conclusion. The value of periostin as a marker of allergic inflammation was shown not only in patients with bronchial asthma, but also in COPD patients. In this regard, it seems promising to use this protein as a predictor of the efficacy of therapy with inhaled GCS in case of COPD. The structural heterogeneity of the periostin molecule requires standardization of the reagents used for its determination and data validation on a large sample size.
Keywords: obstructive disorders, periostin, exacerbation, allergy, bronchial asthma, chronic obstructive pulmonary disease, inflammation
Read entire article

Literature


  1. Sunadome H., Matsumoto H., Tohda Y. et al. Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort. Allergol Int. 2021; 70(2): 252–54. doi: 10.1016/j.alit.2020.10.006.

  2. Buhl R., Korn S., Menzies-Gow A. et al. Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma. J Allergy Clin Immunol Pract. 2020; 8(8): 2630–39. doi: 10.1016/j.jaip.2020.03.038.

  3. Потапова Н.Л., Гаймоленко И.Н. Биомаркеры ремоделирования дыхательных путей при бронхиальной астме. Доктор.Ру. 2020; 11: 27–31. [Potapova N.L., Gaimolenko I.N. Biomarkers of respiratory tract remodelling in bronchial asthma. Doctor.Ru. 2020; 11: 27–31 (In Russ.)]. https://dx.doi.org/10.31550/1727-2378-2020-19-11-27-31.

  4. Шахова Н. В. Периостин – биомаркер бронхиальной астмы. Вопросы современной педиатрии. 2019; 5: 339–345. [Shakhova N.V. Periostin as a biomarker of bronchial asthma. Voprosy sovremennoi pediatrii = Issues of Modern Pediatrics. 2019; 5: 339–345 (In Russ.)]. https://dx.doi.org/10.15690/vsp.v18i5.2056.

  5. Jeanblanc N.M., Hemken P.M., Datwyler M.J. et al. Development of a new ARCHITECT automated periostin immunoassay. Clinica Chimica Acta. 2017; 464: 228–35. doi: 10.1016/j.cca.2016.10.020.

  6. Cai L., Brophy R.H., Tycksen E.D. Distinct expression pattern of periostin splice variants in chondrocytes and ligament progenitor cells. FASEB J. 2019; 33(7): 8386–405. doi: 10.1096/fj.201802281R.

  7. Gadermaier E., Tesarz M., Suciu A.A.-M. et al. Characterization of a sandwich ELISA for the quantification of all human periostin isoforms. J Clin Lab Anal. 2018; 32(2): e22252. doi: 10.1002/jcla.22252.

  8. Соботюк Н.В., Гапоненко В.П., Бочанцев С.В. с соавт. Потенциальная роль сывороточного периостина в ранней диагностике бронхиальной астмы у детей. Вопросы современной педиатрии. 2016; 5: 452–456. [Sobotyuk N.V., Gaponenko V.P., Bochantsev S.V. et al. Potential role of serum periostin in the early detection of bronchial asthma in children. Voprosy sovremennoi pediatrii = Issues of Modern Pediatrics. 2016; 5: 452–456 (In Russ.)]. https://dx.doi.org/10.15690/vsp.v15i5.1619.

  9. Масальский C.С., Калмыкова А.С., Уханова О.П. с соавт. Обзор роли периостина – нового биологического маркера при бронхиальной астме. Российский аллергологический журнал. 2014; 6: 5–8. [Masalskiy S.S., Kalmikova A.S., Ukhanova O.P. et al. Review of the role of periostin as a novel biomarker of bronchial asthma. Rossiyskiy allergicheskiy zhurnal = Russian Allergic Journal. 2014; 6: 5–8 (In Russ.)].

  10. Balbi C., Milano G., Fertig T.E. et al. An exosomal-carried short periostin isoform induces cardiomyocyte proliferation. Theranostics. 2021; 11(12): 5634–49. doi: 10.7150/thno.57243.

  11. Gineyts E., Bonnet N., Bertholon C. et al. The C-terminal intact forms of periostin (iPTN) are surrogate markers for osteolytic lesions in experimental breast cancer bone metastasis. Calcif Tissue Int. 2018; 103(5): 567–80. doi: 10.1007/s00223-018-0444-y.

  12. Свистушкин В.М., Чичкова Н.В., Пшонкина Д.М. Периостин – новый биологический маркер эозинофильного воспаления у больных полипозным риносинуситом и бронхиальной астмой. Таврический медико-биологический вестник. 2017; 3: 232–239. [Svistushkin V.M., Chichkova N.V., Pshonkina D.M. Periostin New biological of eosinophilic inflammation in patients with chronic rhinosinusitis with nasal polyps and bronchial asthma. Tavricheskiy medico-biologicheskiy vestnik = Tavrichesky Medical and Biological Bulletin. 2017; 3: 232–239 (In Russ.)].

  13. Bai Y., Nakamura M., Zhou G. et al. Novel isoforms of periostin expressed in the human thyroid. Jpn Clin Med. 2010; 1: 13–20. doi: 10.4137/JCM.S5899.

  14. Terpos E., Christoulas D., Kastritis E. et al. High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. Blood Cancer J. 2016; 6(10): e482. doi: 10.1038/bcj.2016.90.

  15. Kerschan-Schindl K., Ebenbichler G., Foeger-Samwald U. et al. Rheumatoid arthritis in remission: Decreased myostatin and increased serum levels of periostin. Wien Klin Wochenschr. 2019; 131(1–2): 1–7. doi: 10.1007/s00508-018-1386-0.

  16. Reindel R., Kim K.-Y.A., Baker S.C. et al. Periostin is upregulated in coronary arteriopathy in kawasaki disease and is a potential diagnostic biomarker. Pediatr Infect Dis J. 2014; 33(6): 659–61. doi:10.1097/INF.0000000000000233.

  17. Mansur A.H., Srivastava S., Sahal A. Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function. Respir Med. 2018; 143: 31–38. doi: doi.org/10.1016/j.rmed.2018.08.005.

  18. Ohta S., Okamoto M., Fujimoto K. et al. The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS ONE. 2017; 12(3): e0174547. doi: 10.1371/journal.pone.0174547.

  19. Nejman-Gryz P., Gorska K., Paplinska-Goryca M. et al. Periostin and thymic stromal lymphopoietin – potential crosstalk in obstructive airway diseases. J Clin Med. 2020; 9(11): 3667. doi:10.3390/jcm9113667.

  20. Ono J., Takai M., Kamei A. et al. Periostin forms a functional complex with IgA in human serum. Allergol Int. 2020; 69(1): 111–20. doi: 10.1016/j.alit.2019.05.014.

  21. Thomson N.C., Chaudhuri R., Spears M. et al. Serum periostin in smokers and never smokers with asthma. Respir Med. 2015; 109(6): 708–15. doi: 10.1016/j.rmed.2015.03.009.

  22. Bazan-Socha S., Mastalerz L., Cybulska A. et al. Prothrombotic state in asthma is related to increased levels of inflammatory cytokines, IL-6 and TNFα, in peripheral blood. Inflammation. 2017; 40(4): 1225–35. doi: 10.1007/s10753-017-0565-x.

  23. Scichilone N., Crimi C., Benfante A. et al. Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics. Asthma Res Pract. 2016; 2: 1. doi: 10.1186/s40733-015-0019-x.

  24. Масальский С.С., Калмыкова А.С., Уханова О.П. с соавт. Использование сывороточного периостина в качестве маркера обострений астмы у детей. Аллергология и иммунология в педиатрии. 2018; 4: 37–48. [Masalskiy S.S., Kalmykova A.S., Ukhanova O.P. et al. Use serum periostin as marker of worsening pediatric allergic asthma. Allergologiya i immulogiya v pediatrii = Allergology and Immunology in Pediatrics. 2018; 4: 37–48 (In Russ.)].

  25. Масальский С.С., Калмыкова А.С., Уханова О.П. Роль периостина в фенотипировании аллергической бронхиальной астмы у детей. Российский аллергический журнал. 2017; 1: 88–90. [Masalskiy S.S., Kalmykova A.S., Ukhanova O.P. The role periostin in phenotyping of allergic bronchial asthma in children. Rossiyskiy allergicheskiy zhurnal = Russian Allergic Journal. 2017; 1: 88–90 (In Russ.)].

  26. Cianchetti S., Cardini C., Puxeddu I. et al. Distinct profile of inflammatory and remodelling biomarkers in sputum of severe asthmatic patients with or without persistent airway obstruction. World Allergy Organ J. 2019; 12(11): 100078. doi: 10.1016/j.waojou.2019.100078.

  27. Wang J., Li M.-J., Chang C. Quantitative computed tomography measurement of cross-sectional area of small pulmonary vessels in asthmatic patients. Chin Med J (Engl). 2019; 132(16): 1903–08. doi: 10.1097/CM9.0000000000000367.

  28. Pavlidis S., Takahashi K., Kwong F.N.K. et al. «T2-high» in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Eur Respir J. 2019; 53(1): 1800938. doi: doi.org/10.1183/13993003.00938-2018.

  29. Mena H.M., Abejon D.P.V., Vidigal R.F.F. et al. Role of periostin in uncontrolled asthma in children (DADO study). J Investig Allergol Clin Immunol. 2017; 27(5): 291–98. doi: 10.18176/jiaci.0144.

  30. Ненашева Н.М. Значение биомаркеров в диагностике и терапии бронхиальной астмы. Практическая пульмонология. 2017; 4: 3–9. [Nienasheva N.M. Significance of biomarkers to diagnose and cure bronchial asthma. Prakticheskaya pul’monologiya = Practical Pulmonology. 2017; 4: 3–9 (In Russ.)].


About the Autors

Dmitry Z. Baranov, postgraduate student of the Department of hospital therapy, Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia. Address: 197022, Saint Petersburg, 6–8 L. Tolstogo Str. Tel.: +7 (981) 984-81-26. E-mail: baranovdz@mail.ru. ORCID: 0000-0002-2551-1160
Vasily I. Trofimov, MD, professor, head of the Department of hospital therapy, Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia. Address: 197022, Saint Petersburg, 6–8 L. Tolstogo Str. E-mail: trofvi@mail.ru. ORCID: 0000-0002-6430-6960
Sergey V. Lapin, PhD, head of the laboratory of diagnostics of autoimmune diseases of the Scientific and methodological center of molecular medicine, Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia. Address: 197022, Saint Petersburg, 6–8 L. Tolstogo Str. E-mail: svlapin@mail.ru. ORCID: 0000-0002-4998-3699
Alexandra V. Mazing, PhD, leading researcher of the laboratory of molecular diagnostics, Scientific and methodological center of molecular medicine, Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia. Address: 197022, Saint Petersburg, 6–8 L. Tolstogo Str. E-mail: alex_mazing@mail.ru. ORCID: 0000-0002-3055-6507
Irina V. Kholopova, doctor of clinical laboratory diagnostics of clinical diagnostical laboratory, Scientific and methodological center for molecular medicine, Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia. Address: 197022, Saint Petersburg, 6–8 L. Tolstogo Str. E-mail: irinakholopova@yandex.ru. ORCID: 0000-0001-9520-453X
Darya A. Kuznetsova, PhD, doctor of clinical laboratory diagnostics of clinical diagnostical laboratory, Scientific and methodological center for molecular medicine, Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia. Address: 197022, Saint Petersburg, 6–8 L. Tolstogo Str. E-mail: lariwar@mail.ru. ORCID: 0000-0001-5318-354X
Anna N. Moshnikova, doctor of clinical laboratory diagnostics of clinical diagnostical laboratory, Scientific and methodological center for molecular medicine, Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia. Address: 197022, Saint Petersburg, 6–8 L. Tolstogo Str. E-mail: moshnikova-anna@mail.ru. ORCID: 0000-0002-4604-0660
Tatiana V. Blinova, PhD, senior researcher of laboratory for autoimmune diseases diagnostics, Scientific and methodological center of molecular medicine, Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia. Address: 197022, St. Petersburg, Saint Petersburg, 6–8 L. Tolstogo Str. E-mail: tvblinova@list.ru, ORCID: 0000-0003-4896-3319


Similar Articles

Back to Content

Бионика Медиа